The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

JM Financial forecasts Jio's ARPU to rise 4.5% QoQ to ₹204. Bharti Airtel is expected to see 4.8% QoQ growth in India ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

The Indian economy has seen a sharp slowdown, with real GDP growth falling from 8.2 per cent in FY24 to 6 per cent in the first half of FY25. The report highlights a convergence in real and nominal ...

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

India Inc. is bracing for mixed Q3 results, with earnings growth expected to slow. Analysts predict a 2% Nifty EPS growth for ...

The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".

Media companies are likely to report a subdued performance in the upcoming Q3FY25 results, according to a report by Nuvama.